KLAC
71
4
AEP
61
2
APD
59
14
ACN
42
4
MCD
50
3
JWN
73
-3
ALL
47
-3
ADI
70
2
ROP
71
6
MCHP
62
2
NWL
41
-6
MCO
81
3
SYK
60
7
TGT
57
-2
HCA
57
4
HPE
50
14
CHRW
56
-3
CME
50
-5
VRSK
75
-2
CCI
52
3
KLAC
71
4
AEP
61
2
APD
59
14
ACN
42
4
MCD
50
3
JWN
73
-3
ALL
47
-3
ADI
70
2
ROP
71
6
MCHP
62
2
NWL
41
-6
MCO
81
3
SYK
60
7
TGT
57
-2
HCA
57
4
HPE
50
14
CHRW
56
-3
CME
50
-5
VRSK
75
-2
CCI
52
3
Financhill
Back

NovaBay Pharmaceuticals 10K Form

Sell
37

NBY
NovaBay Pharmaceuticals

Last Price:
0.12
Seasonality Move:
1.9%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive NBY News And Ratings

See the #1 stock for the next 7 days that we like better than NBY

NBY Financial Statistics

Sales & Book Value

Annual Sales: $14.73M
Cash Flow: $-1.57M
Price / Cash Flow: 0
Annual Sales: $-0.04
Price / Book: 0

Profitability

EPS (TTM): -2.60650
Net Income (TTM): $-11.12M
Gross Margin: $7.9M
Return on Equity: -198.74%
Return on Assets: -95.69%

NovaBay Pharmaceuticals Earnings Forecast

Key NovaBay Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 21 years for NBY is 53.61%.
  • The Selling, General & Administrative Expenses for NBY have been equal to 87.12% of Gross Profit Margin.
  • The Research & Development expenses have been 0.46% of Revenue.
  • The Net Earning history of NBY is -65.46% of Total Revenues.
  • Per Share Earnings over the last 21 years have been positive in 11 years.

NovaBay Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYAM
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: NBY
CUSIP: 66987P
Website: novabay.com

Debt

Debt-to-Equity Ratio: 6.29
Current Ratio: 0.92
Quick Ratio: 0.65

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 4.18

NBY Technical Analysis vs Fundamental Analysis

Sell
37
NovaBay Pharmaceuticals (NBY) is a Sell

Is NovaBay Pharmaceuticals a Buy or a Sell?